Deroximel DR Capsule (Enteric Coated) EC Capsule 231 mg belongs to the generic category of Diroximel Fumarate. This medicine should be used according to a doctor's advice. We have provided detailed information about the uses, dosage, effectiveness, side effects, precautions, drug interactions, storage conditions, and other important details of Deroximel DR Capsule (Enteric Coated) EC Capsule 231 mg. Our goal is to present essential medicine information in one place for patients, caregivers, and healthcare professionals. To better understand Diroximel Fumarate and ensure the safe use of this medicine, please read the information below carefully and consult a healthcare professional when necessary.

*Up to 10% Discount
(Depends on pharmacy)
/ Piece
Deroximel DR Capsule (Enteric Coated) EC Capsule 231 mg may be available as a prescription or over-the-counter medicine, depending on local regulations and medical recommendations. It is used for the treatment and management of specific conditions or symptoms. The way this medicine is used may vary depending on the patient's condition and the advice of a healthcare provider. Detailed information about the approved uses, therapeutic applications, and other relevant details of Deroximel DR Capsule (Enteric Coated) EC Capsule 231 mg is provided below to help users gain a clear understanding of this medicine.
Deroximel DR is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
The mechanism by which Deroximel DR Capsule (Enteric Coated) EC Capsule 231 mg (Diroximel Fumarate) exerts its therapeutic effect in multiple sclerosis is unknown. MMF, the active metabolite of diroximel fumarate, has been shown to activate the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway in vitro and in vivo in animals and humans. The Nrf2 pathway is involved in the cellular response to oxidative stress. MMF has been identified as a nicotinic acid receptor agonist in vitro.
Blood Tests Prior to Initiation of Deroximel DR Capsule (Enteric Coated) EC Capsule 231 mg (Diroximel Fumarate) : Obtain the following prior to treatment with Diroximel: A complete blood cell count (CBC), including lymphocyte count Serum aminotransferase, alkaline phosphatase, and total bilirubin levels Dosing Information : The starting dosage for Diroximel is 231 mg twice a day orally. After 7 days, the dosage should be increased to the maintenance dosage of 462 mg (administered as two 231 mg capsules) twice a day orally. Temporary dosage reductions to 231 mg twice a day may be considered for individuals who do not tolerate the maintenance dosage. Within 4 weeks, the recommended dosage of 462 mg twice a day should be resumed. Discontinuation of Diroximel should be considered for patients unable to tolerate return to the maintenance dosage. Administration of non-enteric coated aspirin (up to a dose of 325 mg) 30 minutes prior to Diroximel dosing may reduce the incidence or severity of flushing. Administration Instructions : Swallow Diroximel capsules whole and intact. Do not crush or chew, or sprinkle the capsule contents on food. If taken with food, avoid a high-fat, high-calorie meal/snack; the meal/snack should contain no more than 700 calories and no more than 30 g fat.
The following important adverse reactions are shown: Anaphylaxis and Angioedema Progressive Multifocal Leukoencephalopathy Herpes Zoster and Other Serious Opportunistic Infections Lymphopenia Liver Injury Flushing
Anaphylaxis and Angioedema : Discontinue and do not restart Deroximel DR Capsule (Enteric Coated) EC Capsule 231 mg (Diroximel Fumarate) if these occur. Progressive Multifocal Leukoencephalopathy (PML) : Withhold diroximel at the first sign or symptom suggestive of PML. Herpes zoster and other serious opportunistic infections : Consider withholding diroximel in cases of serious infection until the infection has resolved. Lymphopenia : Obtain a CBC including lymphocyte count before initiating diroximel, after 6 months, and every 6 to 12 months thereafter. Consider interruption of diroximel if lymphocyte counts <0.5 × 109/L persist for more than six months. Liver Injury : Obtain serum aminotransferase, alkaline phosphatase, and total bilirubin levels before initiating diroximel and during treatment, as clinically indicated. Discontinue diroximel if clinically significant liver injury induced by diroximel is suspected.
There are no adequate data on the developmental risk associated with the use of Diroximel or dimethyl fumarate (which has the same active metabolite as Diroximel) in pregnant women. There are no data on the presence of Deroximel DR Capsule (Enteric Coated) EC Capsule 231 mg (Diroximel Fumarate) or metabolites (MMF, HES) in human milk. The effects on the breastfed infant and on milk production are unknown.
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children. Thanks for using MedEx! How would you rate your experience so far?
Data Source: Data source of Indications and Usages, Pharmacology, Dosage & Administration, Drug Interactions, Side Effects, Use during Pregnancy & Lactation, Precautions & Warnings, Use in Special Populations, Therapeutic Class, and Storage Conditions is the concerned medicine company or respective organization.
The information provided on All Samadhan is intended for general informational purposes only and is prepared based on our best practices. It is not a substitute for professional medical advice, diagnosis, or treatment. While we strive to keep the information accurate and up to date, we do not guarantee its completeness or accuracy. The absence of specific information or warnings about any medicine or service should not be considered as an assurance or endorsement by All Samadhan. All Samadhan shall not be held responsible for any consequences arising from the use of this information. We strongly recommend consulting a qualified healthcare professional or physician for any medical concerns, questions, or clarifications.All Samadhan is a digital healthcare software platform operated by MS Genius Experts. We provide technology solutions for pharmacies and healthcare providers; we are not a direct seller or dispenser of prescription medicines

N.B.: All Samadhan is a digital healthcare software platform operated by MS Genius Experts. We provide technology solutions for pharmacies and healthcare providers; we are not a direct seller or dispenser of prescription medicines.
Copyright © All Samadhan - Operated by M/S. Genius Experts | All Rights Reserved
DBID
Registration ID: 176322642
Trade License: TRAD/DNCC/040904/2023